NCT00237913已完成3 期
A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)
Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家目标入组 700 人开始时间: 2004年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 700
- 试验地点
- 1
- 主要终点
- Score on the Investigator Assessment Questionnaire at week 26
研究概览
简要总结
Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of schizophrenia
- •Schizophrenia symptoms not optimally controlled or antipsychotic medication not well tolerated
排除标准
- •Diagnosis of schizoaffective disorder
- •Patients treatment-resistant to antipsychotics
研究组 & 干预措施
A1
Active Comparator
干预措施: Aripiprazole (Drug)
B1
Active Comparator
干预措施: Olanzapine or Quetiapine or Risperidone (Drug)
结局指标
主要结局
Score on the Investigator Assessment Questionnaire at week 26
次要结局
- Clinical Global Impression scale and patient preference of medication at endpoint
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
SWitching to Abilify Trial (SWAT)SchizophreniaNCT00304616Korea Otsuka Pharmaceutical Co., Ltd.500
已完成
3 期
Study of Aripiprazole in Patients With Acute Bipolar ManiaBipolar DisorderNCT00097266Otsuka Pharmaceutical Development & Commercialization, Inc.615
已完成
3 期
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I DisorderBipolar Disorder ManiaNCT00665366Otsuka Pharmaceutical Development & Commercialization, Inc.493
已完成
3 期
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).Autistic DisorderNCT00332241Otsuka Pharmaceutical Development & Commercialization, Inc.98
已完成
3 期
Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's DisorderTourette's DisorderTic DisorderNCT01727700Otsuka Pharmaceutical Development & Commercialization, Inc.133